维普中文期刊产品整合服务
8篇 您的检索式:作者名="Benjamin R Martin"
    题名 作者 年代 出处 被引量
12018加拿大心境障碍与焦虑障碍治疗协作组/国际双相障碍学会指南:双相障碍的管理显示文摘加拿大心境障碍与焦虑障碍治疗协作组(Canadian Network for Mood and Anxiety Treatments,CANMAT)曾于2005年发布了第1版双相障碍管理指南,并分别于2007、2009和2013年对该指南进行了更新,其中最近的2次更新是与国际双相障碍学会(International Society for Bipolar Disorders,ISBD)合作完成。2018版CANMAT/ISBD双相障碍治疗指南(以下简称指南)反映了自2005年首版指南发表以来本领域取得的重大进展,包括疾病诊断与疾病管理的更新以及药物治疗与心理治疗的近期研究进展。这些前沿进展中综合考虑了循证证据的级别,并基于治疗疗效、临床实践经验、安全性、耐受性和药物导致的转相风险等,对一线、二线及三线治疗方案进行了简明而清晰的推荐。本指南中新增内容涵盖了双相Ⅰ型障碍(BD-Ⅰ)的躁狂发作急性期、抑郁发作急性期和双相障碍维持期的一线及二线治疗推荐等级划分。这种对治疗推荐等级的划分综合考虑了治疗方法对双相障碍不同时相的影响,将进一步帮助临床医生做出基于循证证据的治疗决策。锂盐、喹硫平、双丙戊酸盐、阿塞那平、阿立哌唑、帕利哌酮、利培酮和卡利拉嗪单药或联合使用被推荐为躁狂发作急性期的一线治疗选择。BD-Ⅰ抑郁期的一线治疗选择包括喹硫平、鲁拉西酮、锂盐、拉莫三嗪单药,鲁拉西酮联合锂盐或双丙戊酸盐或拉莫三嗪辅助治疗。尽管急性期治疗有效的药物通常应继续用于BD-Ⅰ的维持期治疗,但也存在一些特殊情况(例如抗抑郁药)。现有数据表明,锂盐、喹硫平、双丙戊酸盐、拉莫三嗪、阿塞那平和阿立哌唑单药或联合治疗应被视为维持治疗的初始或更换治疗方案时的一线选择。除了探讨BD-Ⅰ的相关问题外,本指南中还对双相Ⅱ型障碍(BD-Ⅱ)的临床管理进行了系统回顾并给予治疗推荐,同时针对特殊人群也有相关推荐,如处于各个生殖周期的女性、儿童、青少年和老年人。此外,本指南中还讨论了特定精神疾病及共病(如物质滥用、焦虑障碍和代谢性疾病)的影响。最后,本指南中概述了安全性和药物监测的相关问题。CANMAT/ISBD工作组希望本指南能够成为全球临床医生的实用工具。Lakshmi N Yatham Sidney H Kennedy Sagar V Parikh Ayal Sehaffer David J Bond Benicio N Frey Verinder Sharma Benjamin I Goldstein Soham Rej Serge Beaulieu Martin Alda Glenda MaeQueen Roumen V Milev Arun Ravindran Claire O'Donovan Diane Mclntosh Raymond W Lam Gustavo Vazquez Flavio Kapczinski Roger S Melntyre Jan Kozicky Shigenobu Kanba Beny Lafer Trisha Suppes Joseph R Calabrese Eduard Vieta Gin Malhi Robert M Post Michael Berk 胡晨(译) 王刚(译) 2019中华精神科杂志2019,52,1:25
2Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial显示文摘Ronald P DeMatteo Karla V Ballman Cristina R Antonescu Robert G Maki Peter WT Pisters George D Demetri Martin E Blackstein Charles D Blanke Margaret von Mehren Murray F Brennan Shreyaskumar Patel Martin D McCarter Jonathan A Polikoff Benjamin R Tan Kouros 2009The Lancet2009,,9669:2
3Layer-by-Layer Assembly of Ultrathin Composite Films from Micron-Sized Graphite Oxide Sheets and Polyeations 显示文摘Nina I Kovtyukhova Patricia J Ollivier Benjamin R Martin 1999Chem Mater1999,11,77:1
4Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial显示文摘Ronald P DeMatteo Karla V Ballman Cristina R Antonescu Robert G Maki Peter WT Pisters George D Demetri Martin E Blackstein Charles D Blanke Margaret von Mehren Murray F Brennan Shreyaskumar Patel Martin D McCarter Jonathan A Polikoff Benjamin R Tan Kouros 2009The Lancet2009,,9669:1
5Amyotrophic lateral sclerosis显示文摘Matthew C Kiernan Steve Vucic Benjamin C Cheah Martin R Turner Andrew Eisen Orla Hardiman James R Burrell Margaret C Zoing 2011The Lancet2011,,9769:1
6Expression of acoldadapted fish trypsin in Picha pastoris显示文摘MARTIN BENJAMIN R S BYONG B L 2005Yeast Res2005,5,9:1
7Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial显示文摘Ronald P DeMatteo Karla V Ballman Cristina R Antonescu Robert G Maki Peter WT Pisters George D Demetri Martin E Blackstein Charles D Blanke Margaret von Mehren Murray F Brennan Shreyaskumar Patel Martin D McCarter Jonathan A Polikoff Benjamin R Tan Kouros 2009The Lancet2009,,9669:1
8Dense matter with eXTP显示文摘In this White Paper we present the potential of the Enhanced X-ray Timing and Polarimetry(eXTP) mission for determining the nature of dense matter; neutron star cores host an extreme density regime which cannot be replicated in a terrestrial laboratory. The tightest statistical constraints on the dense matter equation of state will come from pulse profile modelling of accretion-powered pulsars, burst oscillation sources, and rotation-powered pulsars. Additional constraints will derive from spin measurements, burst spectra, and properties of the accretion flows in the vicinity of the neutron star. Under development by an international Consortium led by the Institute of High Energy Physics of the Chinese Academy of Sciences, the eXTP mission is expected to be launched in the mid 2020 s.Anna L.Watts WenFei Yu Juri Poutanen Shu Zhang Sudip Bhattacharyya Slavko Bogdanov Long Ji Alessandro Patruno Thomas E.Riley Pavel Bakala Altan Baykal Federico Bernardini Ignazio Bombaci Edward Brown Yuri Cavecchi Deepto Chakrabarty Jér?me Chenevez Nathalie Degenaar Melania Del Santo Tiziana Di Salvo Victor Doroshenko Maurizio Falanga Robert D.Ferdman Marco Feroci Angelo F.Gambino MingYu Ge Svenja K.Greif Sebastien Guillot Can Gungor Dieter H.Hartmann Kai Hebeler Alexander Heger Jeroen Homan Rosario Iaria Jean in 't Zand Oleg Kargaltsev Aleksi KurkelaTheoretical Physics Department CERN XiaoYu Lai Ang Li XiangDong Li ZhaoSheng Li Manuel Linares FangJun Lu Simin Mahmoodifar Mariano Méndez M.Coleman Miller Sharon Morsink Joonas N?ttil? Andrea Possenti Chanda Prescod-Weinstein JinLu Qu Alessandro Riggio Tuomo Salmi Andrea Sanna Andrea Santangelo Hendrik Schatz Achim Schwenk LiMing Song Eva?rámková Benjamin Stappers Holger Stiele Tod Strohmayer Ingo Tews Laura Tolos Gabriel T?r?k David Tsang Martin Urbanec Andrea Vacchi RenXin Xu YuPeng Xu Silvia Zane GuoBao Zhang ShuangNan Zhang WenDa Zhang ShiJie Zheng Xia Zhou 2019Science China(Physics,Mechanics & Astronomy)2019,62,2:0
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费